Monday, October 5, 2015

New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment

New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment

Liz Highleyman
Produced in collaboration with hivandhepatitis.com
Published: 05 October 2015

A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta – EDP-239 – was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in a single-dose monotherapy study presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Diego, USA. Other researchers reported that HCV co-infection and progressive liver disease contribute to mortality among people with HIV, offering further evidence in support of prompt hepatitis C treatment.

No comments:

Post a Comment